Navigation Links
Novel tuberculosis vaccine in Germany in clinical phase
Date:9/11/2008

For the first time in more than 80 years a promising live vaccine against tuberculosis has passed into the clinical phase in Germany: Since Monday of this week the new vaccine, which goes by the designation "VPM1002", has begun safety testing on volunteers in a Phase I clinical trial in Neuss, Germany. It is based on a highly safe vaccine that was introduced in 1921. However, the vaccine has been genetically developed to an extent where it is significantly more effective at preventing infection with tuberculosis bacteria than its predecessor. So far, VPM1002 has proved to be extremely effective and safe in animal models. This good protection now has to be proven in humans for the vaccine to be ready for the final approval," explains the Chief Executive Officer of Vakzine Projekt Management GmbH (VPM), Bernd Eisele.

VPM coordinates application-oriented development of vaccines. The organisation is a public-private partnership established by the Federal Ministry of Education and Research (BMBF) and Helmholtz Centre for Infection Research in 2002. We ensure that the outstanding results of basic science are actually used for the good of mankind and make their way into use," says the Clinical Project Manager Hans von Zepelin. In this, the superb contacts enjoyed by VPM within German science prove a great aid, as the Scientific and Technical Services Manager at the Helmholtz Centre for Infection Research, Rudi Balling, states: "VPM knows exactly where promising projects can be found. With their assistance we, the researchers, can show that our ideas are helping people to stay healthy."

With the financial support of the BMBF VPM was able to licence the novel tuberculosis vaccine from the Max Planck Institute for Infection Biology. The scientific foundation was established in this institute by its Founding Director Stefan H.E. Kaufmann. "The new vaccine is based on the most administered live-vaccine worldwide: Bacille Calmette-Gurin (BCG). However, BCG often fails to display effects anymore. We wanted to sharpen the blunted weapon that is BCG once again."

How this was achieved is described by Leander Grode, at that time a research assistant with Stefan H.E. Kaufmann and now Project Manager at VPM: "The weakened vaccine was genetically modified in such a way to ensure that it is no longer able to hide from the human immune system and even stimulates the body's own defences now." For that a gene of a different bacterium, Listeria, was inserted into the vaccine. "Macrophages of the human immune system take up the vaccine immediately. There it ends up in phagosomes", says Grode. "Due to the genetic modification the bacteria can leave the phagosomes and are then present in the middle of the immune cell this alarms the rest of the immune system, which is then armed to repel real tuberculosis pathogens."


'/>"/>

Contact: Hanner Schlender
hannes.schlender@helmholtz-hzi.de
49-531-618-11400
Helmholtz Association of German Research Centres
Source:Eurekalert  

Related medicine news :

1. VCU Massey Cancer Center spearheads novel clinical study for lymphoma patients
2. Urigen Announces Issuance of Key Patent for URG101 - A Novel Therapy to Treat Painful Bladder Syndrome/Interstitial Cystitis
3. Bruker Daltonics Showcasing Novel Proteomics Solutions Based on Mass Spectrometry at the 7th HUPO World Congress 2008
4. NIH scientists find a novel mechanism that controls the development of autoimmunity
5. Sales of Emerging Novel Pain Therapies Will Represent More than One-Fifth of the Total Pain Drug Market by 2023
6. Novel Diagnostic Marker for Acute Kidney Injury Previewed at Abbott-Sponsored Scientific Workshop
7. Toyota Tsusho America, Inc. and Nippon Kayaku Co., Ltd. Announce the Formation of GlycoMark, Inc., a Joint Venture to Develop and Commercialize Novel Biomarkers for Diabetes
8. Finding suggests novel ways to boost vaccination or natural defenses
9. Novel hydrogel systems for dentin regeneration
10. HighPoint Solutions Develops Novel Incentive Compensation Plan for New Benign Prostatic Hyperplasia (BPH) Product
11. Novel model of osteosarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel tuberculosis vaccine in Germany in clinical phase
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology: